Clinical Trial Update: Study of Tasigna®/Nilotinib (AMN107) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas [EARLY_Phase 1]

View source ↗

Summary

This update reports an early-phase 1 trial of nilotinib (Tasigna) in patients with Neurofibromatosis type 1 and plexiform neurofibromas, with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Plexiform Neurofibroma

Drugs mentioned

• Tasigna (nilotinib)

Snippet

Sponsor: Indiana University | Conditions: Neurofibromatosis, NF1 | EARLY_Phase 1 | Status: COMPLETED | Results posted: 2017-04-12